ES2062762T3 - Metodo para tratar el choque septico. - Google Patents

Metodo para tratar el choque septico.

Info

Publication number
ES2062762T3
ES2062762T3 ES91902317T ES91902317T ES2062762T3 ES 2062762 T3 ES2062762 T3 ES 2062762T3 ES 91902317 T ES91902317 T ES 91902317T ES 91902317 T ES91902317 T ES 91902317T ES 2062762 T3 ES2062762 T3 ES 2062762T3
Authority
ES
Spain
Prior art keywords
septic shock
treating septic
antagonist
human
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91902317T
Other languages
English (en)
Inventor
H Fletcher Starnes
John S Abrams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FLETCHER STARNES H
Merck Sharp and Dohme Corp
Original Assignee
FLETCHER STARNES H
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FLETCHER STARNES H, Schering Corp filed Critical FLETCHER STARNES H
Application granted granted Critical
Publication of ES2062762T3 publication Critical patent/ES2062762T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compression-Type Refrigeration Machines With Reversible Cycles (AREA)
  • Spinning Or Twisting Of Yarns (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Treatment Of Sludge (AREA)
  • Fertilizers (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE FACILITA UN METODO DE TRATAMIENTO DEL SHOCK SEPTICO. EL METODO COMPRENDE LA ADMINISTRACION DE UNA CANTIDAD EFICAZ DE UN ANTAGONISTA AL IL-6 HUMANO. PREFERIBLEMENTE, EL ANTAGONISTA ES UN ANTICUERPO MONOCLONAL DE BLOQUEO ESPECIFICO PARA EL IL-6 HUMANO O UNA COMPOSICION DE UN FRAGMENTO O DE UN LIGANTE DERIVADA DEL MISMO.
ES91902317T 1989-12-04 1990-11-30 Metodo para tratar el choque septico. Expired - Lifetime ES2062762T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44519289A 1989-12-04 1989-12-04

Publications (1)

Publication Number Publication Date
ES2062762T3 true ES2062762T3 (es) 1994-12-16

Family

ID=23767939

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91902317T Expired - Lifetime ES2062762T3 (es) 1989-12-04 1990-11-30 Metodo para tratar el choque septico.

Country Status (11)

Country Link
EP (1) EP0504307B1 (es)
JP (1) JPH0747547B2 (es)
AT (1) ATE100331T1 (es)
AU (1) AU648777B2 (es)
CA (1) CA2070424A1 (es)
DE (1) DE69006221T2 (es)
DK (1) DK0504307T3 (es)
ES (1) ES2062762T3 (es)
FI (1) FI922551A (es)
HU (1) HUT64481A (es)
WO (1) WO1991007986A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009138A1 (en) * 1992-10-20 1994-04-28 Cetus Oncology Corporation Interleukin-6 receptor antagonists
JP3525221B2 (ja) * 1993-02-17 2004-05-10 味の素株式会社 免疫抑制剤
RU2139092C1 (ru) * 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Фрагменты антител в терапии
DE4409513C1 (de) * 1994-02-07 1995-10-19 Knoll Ag Verwendung von anti-TNF-Antikörpern als Arzneimittel zur Behandlung von Erkrankungen mit einem erhöhten Interleukin-6 Serumspiegel
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
CN101361972B (zh) * 1994-10-07 2011-05-25 中外制药株式会社 以il-6拮抗剂作为有效成分治疗慢性类风湿性关节炎
EP1001805A1 (en) * 1997-06-18 2000-05-24 The Rockefeller University Methods for identifying antibodies and peptides useful in the treatment of septic shock and experimental arthritis and uses thereof
CN102089326B (zh) 2008-05-13 2014-12-31 诺维莫尼公司 抗白细胞介素-6/白细胞介素-6受体的抗体及其使用方法
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2598666B2 (ja) * 1987-10-19 1997-04-09 忠三 岸本 抗ヒトｂｃｄｆモノクローナル抗体
CA1341588C (en) * 1988-01-26 2009-01-06 Michel Revel Human ifn-beta2/i1-6, its purification and use
JPH03500050A (ja) * 1988-02-02 1991-01-10 シェリング・バイオテック・コーポレーション 免疫グロブリンｅの応答を減少させる方法
EP0399429A1 (en) * 1989-05-22 1990-11-28 Toray Industries, Inc. Anti-human interleukin-6 monoclonal antibody

Also Published As

Publication number Publication date
EP0504307A1 (en) 1992-09-23
HU9201859D0 (en) 1992-09-28
FI922551A0 (fi) 1992-06-03
WO1991007986A1 (en) 1991-06-13
AU7179491A (en) 1991-06-26
JPH0747547B2 (ja) 1995-05-24
FI922551A (fi) 1992-06-03
EP0504307B1 (en) 1994-01-19
JPH05504058A (ja) 1993-07-01
DK0504307T3 (da) 1994-03-21
WO1991007986A8 (en) 2004-04-22
CA2070424A1 (en) 1991-06-05
DE69006221T2 (de) 1994-05-05
HUT64481A (en) 1994-01-28
DE69006221D1 (de) 1994-03-03
ATE100331T1 (de) 1994-02-15
AU648777B2 (en) 1994-05-05

Similar Documents

Publication Publication Date Title
ES2096553T3 (es) Metodo para el tratamiento de choque endotoxico en un animal mamifero.
MY107079A (en) Method of reducing immunoglobulin e responses
ES2062762T3 (es) Metodo para tratar el choque septico.
EA200400930A1 (ru) Блокирующее моноклональное антитело к vla-1 или его применение для лечения воспалительных заболеваний
ES2062032T3 (es) Antagonista de interleuquina-5 para prevenir o reducir la eosinofilia.
FI924278A0 (fi) Bcrf1 antagonister foer skoetsel av epstein-barr-virusinfektioner.
EA200101271A1 (ru) Блокирующее моноклональное антитело к vla-1 и его применение для лечения воспалительных заболеваний

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 504307

Country of ref document: ES